Sleebs Lab

Medicinal Chemistry and Chemical Biology Research Laboratory @WEHI_research #cancer #malaria #infectiousdiseases | views are our own

[Sleebs Lab @Sleebs_Lab]

Pleased @Sleebs_Lab @WEHI_research contributed to research led by Gregory Adams at MSD on the development of peptidomimetics with potent antimalarial activity that target plasmepsin V https://t.co/g1KP5sn5nq

[Sleebs Lab @Sleebs_Lab]

Please to share @Sleebs_Lab @WEHI_research on characterisation of new structural classes that exhibit potent antimalarial activity by targeting plasmepsin X https://t.co/wAAaqA9kof

[ACS Publications Bio & Med Chem Content @ACSBioMed]

In @Sleebs_Lab @WEHI _research discovered the ADHQ chemotype exemplified by WJM590 that exhibits potent antimalarial activity by inhibiting plasmepsin X. #ACSInfectiousDiseases

https://t.co/2r5hBHi6Gh

[Sleebs Lab @Sleebs_Lab]

Pleased @Sleebs_Lab @WEHI_research played a small role in the published research on the discovery of Plasmodium RBC invasion inhibitors lead by Claudia Barnes and Hayley Bullen @BurnetMalaria
https://t.co/wAssXotrCM

[Sleebs Lab @Sleebs_Lab]

Want to know which plasmepsins are the most promising targets of the next generation of antimalarials. Find out in the recently published review by @Sleebs_Lab @WEHI_research
https://t.co/CTnJypKf1K

[Sleebs Lab @Sleebs_Lab]

Pleased @Sleebs_Lab contributed a small role in remarkable team led by Paola Favuzza and Alan Cowman @WEHI_research and David Olsen and John McCauley at MSD that developed MK-7602 now in clinical development for the treatment of malaria.
https://t.co/JXomvdhWPV

[Sleebs Lab @Sleebs_Lab]

Please to share @Sleebs_Lab @WEHI_research latest research led my @MadelineDans and @Wenyin_Su demonstrating the on-target activity of plasmepsin V peptidomimetics in Plasmodium falciparum parasites using genetic and proteomic approaches.
https://t.co/Xgo0ApvVEb

[Sleebs Lab @Sleebs_Lab]

Please @Sleebs_Lab @WEHI_research has contributed to a review at @npjAMR led by Emma Mao @UniofAdelaide on the contribution of natural products to the drugs approved to treat disease caused by apicomplexan parasites
https://t.co/UIi5AfmzMN

[Sleebs Lab @Sleebs_Lab]

Pleased to see our research is published @Sleebs_Lab @WEHI_research led by William Nguyen on the optimization of an antimalarial class that targets ROM8 & CSC1
...stay tuned for more research on the intriguing role of ROM8 & CSC1 in parasite survival...
https://t.co/kHKSVlX0fa

[Christoph Nitsche @NitscheLab]

Truly honoured to receive the #MCCB2025 Peter Andrews Award for Innovation in Medicinal Chemistry and Chemical Biology. Grateful for the recognition of our work at @NitscheLab and @ANUChemistry! Congratulations to @PScammells on the well-deserved Adrien Albert Award!

[Madeline E. Kavanagh @mads_chem]

Exciting Day 3 @RACI #MCCB2025 ! Starting with showstopping stories from GateBioscience's Pat Sharp on the development of Sec61 #inhibitors for Prion disease, & Prof. Avril Robertson @UQ_News on targeting NLRP3 #inflammasomes. Impressive preclinical efficacy fromin both stories!

[Rohan Volpe @rohanvolpe]

#mccb2025 was great for many reasons. Seeing a plenary swim with a croc was one!

[Sleebs Lab @Sleebs_Lab]

Pleased @Sleebs_Lab @WEHI_research has contributed to research led by Aya Taki @UniMelb on the prediction and prioritization of novel anthelmintic candidates using deep learning is published at Int J Mol Sci. https://t.co/wsAHp3PMHw #mdpiijms via @IJMS_MDPI

[Sleebs Lab @Sleebs_Lab]

Pleased to see our research @Sleebs_Lab @WEHI_research lead by Tony Hodder on the structural analysis of dual plasmepsin V and plasmepsin X inhibitors is now online at FEBS. https://t.co/d6n0w3w3wD

[Sleebs Lab @Sleebs_Lab]

Pleased to see the review lead by Harry Shanley @Sleebs_Lab @WEHI_research in collaboration with the Gasser Lab @UniMelb on Advances in Anthelmintic Target Identification is now published. https://t.co/nx0xEsjxy9 #mdpiijms via @IJMS_MDPI

[Sleebs Lab @Sleebs_Lab]

Pleased to see our latest research lead by Kyle Awalt and Zi Kang Ooi @Sleebs_Lab @WEHI_research on the investigation of a novel class of antimalarials that target PfATP4 published is now online at the Journal of Medicinal Chemistry. https://t.co/xbE5MEL6R9

[Christoph Nitsche @NitscheLab]

Great talk from our lab alumnus @s_ullr on SARS-CoV-2 main protease inhibitors at the #MCCB2025!

[Royal Australian Chemical Institute @RACInational]

Thanks for joining MCCB 2025 in Darwin! That’s a wrap on a fantastic conference full of great science, networking & inspiration. Safe travels & see you next time! 🌟 #MCCB2025 #RACI

[Christoph Nitsche @NitscheLab]

Congratulations to @UpamaliSajinika from our lab for receiving the poster prize at the #MCCB2025!

[Royal Australian Chemical Institute @RACInational]

A big THANK YOU to all MCCB 2025 sponsors & exhibitors! Your support drives innovation & makes this conference possible🌟 #MCCB2025